期刊文献+
共找到12篇文章
< 1 >
每页显示 20 50 100
黄芪多糖在Her-2阳性乳腺癌患者化疗中增效减毒的作用及其对血清Her-2-ECD、TAP和疗效的影响
1
作者 周芹芹 林芬 +1 位作者 钟小娟 袁云 《中国医学创新》 CAS 2024年第20期57-62,共6页
目的:探讨黄芪多糖在人表皮生长因子受体-2(human epidermal growth factor receptor-2,Her-2)阳性乳腺癌患者化疗中增效减毒的作用及其对血清人表皮生长因子受体-2胞外段(human epidermal growth factor receptor-2-extracellular doma... 目的:探讨黄芪多糖在人表皮生长因子受体-2(human epidermal growth factor receptor-2,Her-2)阳性乳腺癌患者化疗中增效减毒的作用及其对血清人表皮生长因子受体-2胞外段(human epidermal growth factor receptor-2-extracellular domain,Her-2-ECD)、肿瘤异常糖链糖蛋白(tumor abnormal protein,TAP)和疗效的影响。方法:选择2020年1月—2023年6月新余北湖医院收治的90例Her-2阳性乳腺癌患者作为研究对象,将患者随机分为对照组和观察组,各45例。两组均给予TCbHP(多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗)方案治疗;观察组在此基础上给予注射用黄芪多糖治疗。比较两组治疗前后的中医症候积分、血清Her-2-ECD、TAP水平、免疫功能(CD4^(+)、CD8^(+))、白细胞(white blood cell,WBC)水平、乳腺癌患者的生活质量量表(functional assessment of cancer therapy-breast,FACT-B)评分、疗效及不良反应发生率。结果:治疗前,两组各项中医症候积分、Her-2-ECD、TAP、CD4^(+)、CD8^(+)、WBC、FACT-B评分比较,差异均无统计学意义(P>0.05)。治疗后,观察组各项中医症候评分、Her-2-ECD、TAP、CD8^(+)、FACT-B各项评分及不良反应发生率均低于对照组,CD4^(+)、WBC、总有效率均高于对照组,差异均有统计学意义(P<0.05)。结论:黄芪多糖能够改善Her-2阳性乳腺癌化疗患者的化疗效果,减轻化疗带来的毒性反应,提高患者的生活质量。 展开更多
关键词 黄芪多糖 人表皮生长因子受体-2阳性乳腺癌 化疗 人表皮生长因子受体-2外段 肿瘤异常糖链糖蛋白
下载PDF
白细胞介素-1β促人视网膜色素上皮细胞分泌血管内皮生长因子和碱性成纤维细胞生长因子的研究 被引量:1
2
作者 李莹 张潇 +1 位作者 赵潺 龙琴 《中华眼底病杂志》 CAS CSCD 北大核心 2009年第5期376-379,共4页
目的 观察炎前因子白细胞介素-1β(IL-1β)对培养的人视网膜色素上皮(RPE)细胞分泌血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)的影响。方法采用酶联免疫吸附测定法(ELISA)测定IL—G浓度为0、1、10、20ng/ml和时... 目的 观察炎前因子白细胞介素-1β(IL-1β)对培养的人视网膜色素上皮(RPE)细胞分泌血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)的影响。方法采用酶联免疫吸附测定法(ELISA)测定IL—G浓度为0、1、10、20ng/ml和时间为24、36、48h作用下RPE细胞的VEGF和bFGF分泌量变化;采用半定量逆转录聚合酶链式反应(RTPCR)测定10ng/ml IL-1β作用48h后RPE细胞的VEGF和bFGFmRNA变化;噻唑蓝(MTT)比色法测定IL-1β刺激后RPE细胞的增生状态。结果相同刺激时间即36h作用下,终浓度为1、10ng/ml的IL-1β促进RPE细胞VEGF的分泌(q=32.79,42.56;P〈0.01);10ng/ml的Il-1β促进bFGF的分泌(q=7.514,P<0.01);与浓度为10ng/ml的IL-1β刺激相比,增加IL-1β刺激浓度至20ng/ml使RPE细胞VEGF和bFGF分泌量下降(q=9.35,6.92;P<0.01)。相同浓度即10ng/ml的IL-1β作用下IL-1β作用时间与RPE细胞VEGF和bFGF分泌量具有正性时间-效应关系;浓度为10ng/ml的IL-1β作用48h可促进RPE细胞的VEGF和bFGFmRNA水平;MTT结果证明IL-1β未明显影响RPE细胞的增生状态(F=0.317,P〉0.05)。结论炎前因子IL-1β可影响人RPE细胞VEGF和bFGF的分泌量,在一定的作用浓度和作用时间范围内具有显著的促进效应。 展开更多
关键词 色素上皮 眼/生理学 自细介素1β/投药和剂量 血管内皮生长因子 成纤维细 胞生长因子2
原文传递
灯盏花素对肝纤维化大鼠的干预作用及机制
3
作者 魏丹丹 李闪闪 +9 位作者 张明昊 魏雨润 王红玲 柴爽爽 殷晶晶 张敏 赵菡 吴宗耀 朱奎成 王庆波 《中国药房》 CAS 北大核心 2024年第6期671-677,共7页
目的基于转化生长因子β1(TGF-β1)/Smad2/胞外信号调节激酶1(ERK1)通路和Kelch样环氧氯丙烷相关蛋白1(Keap1)/核转录因子红系2相关因子2(Nrf2)/血红素加氧酶1(HO-1)通路,探讨灯盏花素对肝纤维化(HF)大鼠的干预作用及潜在机制。方法将6... 目的基于转化生长因子β1(TGF-β1)/Smad2/胞外信号调节激酶1(ERK1)通路和Kelch样环氧氯丙烷相关蛋白1(Keap1)/核转录因子红系2相关因子2(Nrf2)/血红素加氧酶1(HO-1)通路,探讨灯盏花素对肝纤维化(HF)大鼠的干预作用及潜在机制。方法将60只大鼠随机分为正常对照组,模型组,灯盏花素低、中、高剂量组(5.4、10.8、21.6 mg/kg)和秋水仙碱组(阳性对照,0.45 mg/kg),每组10只,雌雄各半。除正常对照组外,其余各组大鼠均以四氯化碳诱导构建HF模型。随后,各药物组大鼠灌胃相应药液,每天1次,连续28 d。观察各组大鼠的肝脏外观并计算其肝脏系数,检测其血清中丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)水平和肝组织中ALT、AST、超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)水平,观察其肝组织炎症和纤维化情况,检测肝组织中TGF-β1、Smad、ERK1、Nrf2、Keap1、HO-1蛋白及mRNA的表达情况。结果与正常对照组比较,模型组大鼠肝脏可见大面积的白色结节灶、明显的炎症细胞浸润和胶原纤维沉积;其体重,肝组织中SOD、GSH-Px水平和Nrf2、HO-1蛋白及mRNA的表达水平均显著降低(P<0.05);肝脏系数,Masson染色阳性面积百分比,血清及肝组织中ALT、AST水平,肝组织中MDA水平和TGF-β1、Smad2、ERK1、Keap1蛋白及mRNA的表达水平显著升高(P<0.05)。与模型组比较,各药物组大鼠肝组织病变均有所改善,上述定量指标普遍逆转(P<0.05)。结论灯盏花素对大鼠HF有较好的干预作用,其作用可能与抑制TGF-β1/Smad2/ERK1通路来抗纤维化,调控Keap1/Nrf2/HO-1通路来抑制氧化应激有关。 展开更多
关键词 灯盏花素 肝纤维化 氧化应激 转化生长因子β1/Smad2/外信号调节激酶1通路 Kelch样环氧氯丙烷相关蛋白1/核转录因子红系2相关因子2/血红素加氧酶1通路
下载PDF
血清HER2 ECD+VEGF+HE4对乳腺癌术后复发转移的诊断价值 被引量:7
4
作者 常庆龙 杨红星 +1 位作者 贾国丛 王阳 《癌症进展》 2019年第3期328-330,334,共4页
目的比较血清人类表皮生长因子受体2胞外片段(HER2 ECD)、人附睾蛋白4(HE4)、血管内皮细胞生长因子(VEGF)和HER2 ECD+VEGF+HE4在乳腺癌术后复发转移中的诊断价值,以期选择最佳的检测方法,提高检测乳腺癌术后复发转移的灵敏度。方法选取... 目的比较血清人类表皮生长因子受体2胞外片段(HER2 ECD)、人附睾蛋白4(HE4)、血管内皮细胞生长因子(VEGF)和HER2 ECD+VEGF+HE4在乳腺癌术后复发转移中的诊断价值,以期选择最佳的检测方法,提高检测乳腺癌术后复发转移的灵敏度。方法选取接受手术治疗的86例乳腺癌患者作为研究对象,其中,术后复发转移患者34例(复发组),术后未复发转移患者52例(未复发组);另选取同期体检的40例健康女性作为对照组。检测3组受试者的血清HER2 ECD、VEGF、HE4水平。以病理学诊断结果作为金标准,分析不同检测方法对乳腺癌术后复发转移的的诊断效能。结果复发组患者的血清HER2 ECD、VEGF、HE4水平均高于未复发组和对照组,差异均有统计学意义(P﹤0.05);未复发组患者的血清VEGF、HE4水平均高于对照组,差异均有统计学意义(P﹤0.05)。血清HER2 ECD+VEGF+HE4联合检测乳腺癌术后复发转移的灵敏度为88.24%(30/34),特异度为86.54%(45/52),漏诊率为11.76%(4/34),误诊率为13.46%(7/52)。结论血清HER2 ECD+VEGF+HE4联合检测较三者单独检测能够提高对乳腺癌术后复发转移诊断的灵敏度,具有较高的临床诊断价值。 展开更多
关键词 人类表皮生长因子受体2外片段 人附睾蛋白4 血管内皮细生长因子 乳腺癌 复发转移
下载PDF
Intravenous acid fibroblast growth factor protects intestinal mucosal cells against ischemia-reperfusion injury via regulating Bcl-2/Bax expression 被引量:10
5
作者 WeiChen Xiao-BingFu +6 位作者 Shi-LiGe Tong-ZhuSun GangZhou BingHan Yi-RiDu Hai-HongLi Zhi-YongSheng 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第22期3419-3425,共7页
AIM: To detect the effect of acid fibroblast growth factor (aFGF) on apoptosis and gene expression of bax and bcl-2 gene in rat intestine after ischemia/reperfusion (I/R) injury, and to explore the protective mechanis... AIM: To detect the effect of acid fibroblast growth factor (aFGF) on apoptosis and gene expression of bax and bcl-2 gene in rat intestine after ischemia/reperfusion (I/R) injury, and to explore the protective mechanisms of aFGF.METHODS: One hundred and eight Wistar rats were randomly divided into sham-operated control group (C)(n = 6), intestinal ischemia group (I) (n = 6), aFGF treatment group (A) (n = 48) and intestinal ischemia reperfusion group (R) (n = 48). In group I, the animals were killed after 45 min of superior mesenteric artery (SMA) occlusion, while in groups R and A, the rats sustained 45 min of SMA occlusion and were then treated with normal saline and aFGF, respectively, sustained 15 min, 30 min, 1, 2, 6, 12, 24, or 48 h of reperfusion, respectively. In group C, SMA was separated, but without occlusion. Apoptosis in intestinal villus was determined with terminal deoxynucleotidyl transferase mediated dUTP-biotin nickend labeling technique (TUNEL). Intestinal tissue samples were taken not only for detection of bax and bcl-2 gene expression by RT-PCR, but also for detection of bax and bcl 2 protein expression and distribution by immunohistochemical analysis.RESULTS: The rat survival rates in aFGF treated group were higher than group R (P<0.05) and the improvement of intestinal histological structures was observed at 2, 6, and 12 h after the reperfusion in group A compared with group R. The apoptotic rates were (41.17±3.49)%, (42.83±5.23)% and (53.33±6.92)% at 2, 6 and 12 h after reperfusion, respectively in group A, apparently less than those of group R at matched time points (50.67±6.95, 54.17±7.86, 64.33±6.47, respectively) (P<0.05). The bax gene transcription and translation were significantly decreased in group A vs group R, while mRNA and protein contents of Bcl-2 in group A were obviously higher than those in groupR during 2-12 h period after reperfusion.CONCLUSION: The changes in histological structure and the increment of apoptotic rate indicated that the intestinal barrier was damaged after intestinal I/R injury, whilst intravenous aFGF could alleviate apoptosis induced by ischemia and reperfusion in rat intestinal tissues, in which genes of bax and bcl-2 might play important roles. 展开更多
关键词 Acid fibroblast growth ISCHEMIA REPERFUSION Bcl-2 gene Bax gene
下载PDF
TE化疗联合黄芪多糖注射液治疗中晚期乳腺癌临床疗效及对患者血清HER2-ECD TAP水平的影响 被引量:4
6
作者 仲广生 郝凯峰 张明芳 《临床心身疾病杂志》 CAS 2021年第2期15-20,共6页
目的探讨多西紫杉醇+表柔比星新辅助化疗联合黄芪多糖注射液治疗中晚期乳腺癌临床疗效及对患者血清人表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平的影响。方法将60例中晚期乳腺癌患者按随机数字表法分为两组,各30例。对照组给予... 目的探讨多西紫杉醇+表柔比星新辅助化疗联合黄芪多糖注射液治疗中晚期乳腺癌临床疗效及对患者血清人表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平的影响。方法将60例中晚期乳腺癌患者按随机数字表法分为两组,各30例。对照组给予多西紫杉醇+表柔比星新辅助化疗,观察组在对照组基础上联合黄芪多糖注射液治疗。观察4个疗程。比较治疗前后两组疗效、肿瘤T分期降期率、保乳手术率、Karnofsky功能状态评分、癌症患者生活质量评定量表评分、CD3+、CD4+/CD8+、血清人类表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平、不良反应发生状况,并采用Spearman相关分析探讨血清人表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平与临床疗效的相关性。结果观察组缓解率、T分期降期率、保乳手术率高于对照组(P<0.05或0.01)。治疗后观察组Karnofsky功能状态评分、CD3+、CD4+/CD8+水平显著高于对照组(P<0.01),癌症患者生活质量评定量表评分、血清人类表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平显著低于对照组(P<0.01)。乳腺癌患者血清人类表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平与临床疗效呈显著负相关(P<0.05)。观察组白细胞下降、脱发、血小板下降、恶心呕吐发生率显著低于对照组(P<0.05)。结论多西紫杉醇+表柔比星新辅助化疗联合黄芪多糖注射液治疗中晚期乳腺癌疗效显著,能下调血清人表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平,改善患者功能状况及生活质量,降低不良反应发生率。 展开更多
关键词 乳腺癌 黄芪多糖注射液 化疗 临床疗效 人皮生长因子受体-2外段 肿瘤异常糖链糖蛋白
下载PDF
The impact on secreted VEGF of Hep-2 human laryngeal cancer cell induced by Rg3 被引量:1
7
作者 Jihua Zhang Lai Wang +4 位作者 Caili Han Dongmei Song Baoshan Wang Suqin Shi Sha Liu 《The Chinese-German Journal of Clinical Oncology》 CAS 2013年第10期477-480,共4页
Objective:The aim of this study was to investigate the af ecting of Rg3 to secreted VEGF of human laryngeal carcinoma Hep-2 cells and its mechanism of inhibition to tumor angiogenesis. Methods:Cultured human larynge... Objective:The aim of this study was to investigate the af ecting of Rg3 to secreted VEGF of human laryngeal carcinoma Hep-2 cells and its mechanism of inhibition to tumor angiogenesis. Methods:Cultured human laryngeal cancer cellline Hep-2 and human vascular endothelial cells in vitro, cells got into the period of exponential phase of growth, was diviced into 3 groups:group I (control group), group II (DDP group), group III (Rg3 group). Added to the Hep-2 cells Rg3 and DDP, made Rg3 final concentration was 300μg/mL, and DDP was 3μg/mL. 48 h later, specimens from sample to be done immunocytochemistry, and the protein of VEGF in Hep-2 cells to be detected. Col ecting Hep-2 cells supernatant, some was used to measure the protein level of VEGF in Hep-2 cells supernatant by ELISA. Some was used to culture HVEC. 24 h later, cellgrowth inhibition rate of human vascular endothelial was determined by MTT. Results:The protein level of VEGF was evi-dently higher in group I compared to group II and group III, it was not only in Hep-2 cells, but also in supernatant of Hep-2 cells. There was no significantly dif erent between group II and group III. MTT results showed that, the human vascular endothelial cellgrowth inhibition rate of group I was significantly lower than that of group II and group III (P〈0.05). At the same time the HVEC growth inhibition rate of group II was significantly lower than that of group III (P〈0.05). Conclusion:The inhibition to tumor angiogenesis of Rg3 is stronger than traditional chemotherapy drug cisplatin. It worke by reducing the biological ef ects of secreted VEGF, But the ef ecting worke by reducing the activity of secreted VEGF itself or af ecting endothelial function of VEGF receptor or some other ways to be further studied. 展开更多
关键词 Rg3 secreted VEGF Hep-2 cell HVEC
下载PDF
链霉菌I06A-03304产生的二酮哌嗪类化合物的纯化及结构鉴定 被引量:2
8
作者 蒋忠科 张洋 +2 位作者 郭连宏 姜蓉 孙承航 《中国医药导报》 CAS 2014年第18期4-8,共5页
目的分离鉴定链霉菌I06A-03304发酵液中具血管内皮细胞生长因子受体-2胞内酪氨酸激酶(VEGFR2-CD)抑制活性的次生代谢产物。方法采用大孔吸附树脂、羟丙基葡聚糖凝胶(Sephadex LH-20)、C-18反相色谱(ODS)、高压液相色谱(HPLC)等分离手段... 目的分离鉴定链霉菌I06A-03304发酵液中具血管内皮细胞生长因子受体-2胞内酪氨酸激酶(VEGFR2-CD)抑制活性的次生代谢产物。方法采用大孔吸附树脂、羟丙基葡聚糖凝胶(Sephadex LH-20)、C-18反相色谱(ODS)、高压液相色谱(HPLC)等分离手段对次生代谢产物进行分离纯化;通过二级质谱(ESI+-MS2)、紫外光谱(UV)、红外光谱(IR)、核磁共振波谱(NMR)对其结构进行鉴定,以酶联免疫吸附试验(ELISA)法检测其次生代谢产物对VEGFR2-CD的抑制活性。结果分离得到两个二酮哌嗪类化合物:3304A和3304C;化合物3304A的化学结构与环(脯氨酸-亮氨酸)一致,化合物3304C的化学结构与环(脯氨酸-苯丙氨酸)一致,均对VEGFR2-CD表现出一定的抑制活性。结论化合物3304A和3304C是具有VEGFR2-CD抑制活性的二酮哌嗪类次生代谢产物,并为本研究首次报道。 展开更多
关键词 血管内皮细生长因子受体-2内酪氨酸激酶 链霉菌 二酮哌嗪 拮抗剂
下载PDF
新辅助化疗联合内分泌治疗乳腺癌的临床研究
9
作者 石鑫 《大医生》 2021年第11期21-23,共3页
目的探讨新辅助化疗联合内分泌治疗对乳腺癌患者血清糖类抗原153(CA153)、糖类抗原125(CA125)、人表皮生长因子受体-2胞外段(HER2-ECD)水平的影响。方法按照随机数字表法将山西省中医院2018年1月至2020年1月收治的80例乳腺癌患者分为对... 目的探讨新辅助化疗联合内分泌治疗对乳腺癌患者血清糖类抗原153(CA153)、糖类抗原125(CA125)、人表皮生长因子受体-2胞外段(HER2-ECD)水平的影响。方法按照随机数字表法将山西省中医院2018年1月至2020年1月收治的80例乳腺癌患者分为对照组和观察组,每组40例。对照组患者接受新辅助化疗,观察组患者接受新辅助化疗联合内分泌治疗。对比两组患者治疗结束后临床疗效,治疗前、治疗结束后CA153,CA125,HER2-ECD水平与治疗期间不良反应发生情况。结果治疗结束后观察组患者客观有效率(0RR)较对照组显著升高(P<0.05),两组患者疾病控制率(DCR)比较,差异无统计学意义(P>0.05);治疗结束后两组患者血清CA153、CA125、HER2-ECD水平均较治疗前显著下降,且观察组下降幅度较对照组显著增大(均P<0.05);两组患者白细胞减少、肝功能异常、心脏毒性、恶心呕吐发生率比较,差异均无统计学意义(均P>0.05).结论新辅助化疗联合内分泌治疗乳腺癌能提高化疗效果,降低血清CA153、CA125、HER2-ECD水平,降低肿瘤负荷,且安全性良好。 展开更多
关键词 乳腺癌 新辅助化疗 内分泌治疗 糖类抗原153 糖类抗原125 人表皮生长因子受体-2外段
下载PDF
槐耳颗粒联合TEC新辅助化疗对中晚期乳腺癌患者疾病控制率及血清HER2-ECD、TAP水平的影响 被引量:6
10
作者 尹剑桥 李午生 +3 位作者 韩思佳 邢飞 于宏 邱芳 《中国医师杂志》 CAS 2021年第4期568-572,共5页
目的探讨槐耳颗粒联合多西他赛+表柔比星+环磷酰胺(TEC)新辅助化疗对中晚期乳腺癌患者疾病控制率及血清人类表皮生长因子受体2胞外片段(HER2-ECD)、肿瘤异常蛋白(TAP)水平的影响。方法选取2013年4月至2016年6月中国医科大学附属盛京医... 目的探讨槐耳颗粒联合多西他赛+表柔比星+环磷酰胺(TEC)新辅助化疗对中晚期乳腺癌患者疾病控制率及血清人类表皮生长因子受体2胞外片段(HER2-ECD)、肿瘤异常蛋白(TAP)水平的影响。方法选取2013年4月至2016年6月中国医科大学附属盛京医院收治的中晚期乳腺癌患者94例进行前瞻性研究,以简单随机化法分为观察组(n=47)、对照组(n=47)。对照组予以TEC新辅助化疗,观察组予以TEC新辅助化疗联合槐耳颗粒治疗,均治疗12周。对比两组疗效、不良反应发生率与治疗前、治疗12周后细胞免疫功能指标(CD8+、CD4+、CD4+/CD8+)、血清HER2-ECD、TAP水平,治疗后随访3年,对比两组治疗后1年、2年、3年生存率。结果观察组治疗12周后疾病控制率高于对照组(P<0.05);治疗期间,观察组胃肠道反应、中性粒细胞减少、血小板减少、肝功能异常发生率低于对照组(P<0.05);观察组治疗12周后血清CD8+水平低于对照组,血清CD4+、CD4+/CD8+水平高于对照组(P<0.05);观察组治疗12周后血清HER2-ECD、TAP水平低于对照组(P<0.05);观察组治疗后3年生存率高于对照组(P<0.05)。结论槐耳颗粒联合TEC新辅助化疗治疗中晚期乳腺癌患者,可降低患者血清HER2-ECD、TAP水平,增强机体免疫功能,减轻毒副反应,提高远期生存率,疗效显著。 展开更多
关键词 乳腺肿瘤 化学疗法 辅助 槐耳颗粒 人类表皮生长因子受体2外片段 肿瘤异常蛋白
原文传递
Effect of keratinocyte growth factor-2 on proliferation of human adult keratino cytes 被引量:5
11
作者 杨银辉 付小兵 黎君友 《Chinese Journal of Traumatology》 CAS 2002年第6期342-345,共4页
To investigate the proliferative ef fect of keratinocyte growth factor (KGF 2) on human adult keratinocytes. Methods: The standard medium was keratinocyte growth medium wit hout bovine pituitary extract (BPE), hydroco... To investigate the proliferative ef fect of keratinocyte growth factor (KGF 2) on human adult keratinocytes. Methods: The standard medium was keratinocyte growth medium wit hout bovine pituitary extract (BPE), hydrocortisone or epidermal growth factor ( EGF). Keratinocytes from a 48 year old subject were cultured and seeded on dis hes with standard medium of EGF in cell density of 2×10 4/32 mm 2. After 24 hours, the medium was replaced by the standard medium with 0, 4, 16, 125 and 50 0 ng/ml KGF 2, respectively. The standard medium with EGF was used as the posit ive control and the standard medium without EGF or KGF 2 was used as the negati ve controls. The growth of keratinocytes was monitored by 3 (4,5 dimethythiazo l 2 yl) 2,5 dipheyl tetrazolium bromide (MTT) assay and by photographs on day s 3, 5 and 7, respectively. Results: KGF 2 in concentrations of 4 500 ng/ml showed a sign ificant proliferative effect on days 5 and 7 as compared with that of the negati ve controls (P< 0.01 ). On day 3 the cells were prolifer ated to 1.5 2.5 fold, on day 5 to 3 5 fold and on day 7 to 3 12 fo ld in KGF 2 medium as that of the negative controls. The optimal response occur red when the concentration of KGF 2 was 125 ng/ml on day 7. Cell proliferation was also consistently higher in all KGF 2 concentrations as compared with that of the positive controls. Conclusions: KGF 2 has significant effects on the proliferatio n of adult keratinocytes, which are more effective than that of EGF. This study supports KGF 2 can improve the healing of chronic wounds in adults in clinic. 展开更多
关键词 KERATINOCYTES Proliferating cell nuclear antigen K eratinocyte growth factor 2
原文传递
Cytocompatibility of regenerated silk fibroin film:a medical biomaterial applicable to wound healing 被引量:16
12
作者 Tie-lian LIU Jing-cheng MIAO +4 位作者 Wei-hua SHENG Yu-feng XIE Quan HUANG Yun-bo SHAN Ji-cheng YANG 《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 SCIE CAS CSCD 2010年第1期10-16,共7页
Objective: To explore the feasibility of using regenerated silk fibroin membrane to construct artificial skin substitutes for wound healing, it is necessary to evaluate its cytocompatibility. Methods: The effects of... Objective: To explore the feasibility of using regenerated silk fibroin membrane to construct artificial skin substitutes for wound healing, it is necessary to evaluate its cytocompatibility. Methods: The effects of regenerated silk fibroin film on cytotoxicity, adhesion, cell cycle, and apoptosis of L929 cells, growth and vascular endothelial growth factor (VEGF) expression of ECV304 cells, and VEGF, angiopoietin-1 (Ang-1), platelet-derived growth factor (PDGF) and fibroblast growth factor 2 (FGF2) expression of WI-38 cells were assessed by 3-(4,5)-dimethylthiahiazo (-z-yl)-3,5-di-phenytetrazoliumromide (MTT) assay, viable cell counting, flow cytometry (FCM), and enzyme-linked immunosorbant assay (ELISA). Results: We showed that the regenerated silk fibroin film was not cytotoxic to L929 cells and had no adverse influence on their adhesion, cell cycle or apoptosis; it had no adverse influence on the growth and VEGF secretion of ECV304 cells and no effect on the secretion of VEGF, Ang-1, PDGF and FGF2 by WI-38 cells. Conclusion: The regenerated silk fibroin film should be an excellent biomaterial with good cytocompatibility, providing a framework for reparation after trauma in clinical applications. 展开更多
关键词 Regenerated silk fibroin film CYTOCOMPATIBILITY CYTOTOXICITY
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部